Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 9/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.32 |
| ▸ | PIM1 | P11309 | 3/20 | 0.32 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262248 | 0.90 | MAP2K1 (0.34) | PARP1MAP2K1CLK4DYRK1BFYN | |
| SCHEMBL2730821 | 0.89 | MAP2K1 (0.34) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL3200519 | 0.85 | MAP2K1 (0.36) | PARP1CHUKDYRK1AMAP2K1CLK4 | |
| SCHEMBL3601959 | 0.85 | MAP2K1 (0.36) | PARP1MAP2K1CLK4DYRK1BNTRK1 | |
| SCHEMBL2363030 | 0.84 | NTRK1 (0.43) | DYRK1AMAP2K1CLK4DYRK1BNTRK1 | |
| SCHEMBL3082604 | 0.84 | MAP2K1 (0.49) | PARP1IKBKBMAP2K1CLK4DYRK1B | |
| SCHEMBL15654034 | 0.83 | PARP1 (0.45) | PARP1 | |
| SCHEMBL2365481 | 0.82 | MAP2K1 (0.34) | MAP2K1CLK4DYRK1BNTRK1PIM1 | |
| SCHEMBL15654352 | 0.82 | JAK2 (0.42) | — | |
| SCHEMBL15654312 | 0.82 | JAK2 (0.43) | PARP1IRAK4MAP2K1CLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | ALFASIGMA S.P.A. (IT) | 2024-07-23 | — | — | US | disclosed |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2023-12-21 | — | — | US | disclosed |
| EP-3283114-B1 | METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | GALAPAGOS NV (BE) | 2023-09-06 | — | — | EP | disclosed |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2023-06-06 | — | — | US | disclosed |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2021-12-02 | — | — | US | disclosed |
| EP-3842432-A1 | NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Galapagos N.V. (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2021-05-11 | — | — | US | disclosed |
| US-10919890-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2021-02-16 | — | — | US | disclosed |
| EP-3102575-B1 | NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2021-01-13 | — | — | EP | disclosed |
| US-20200244651-A1 | NOVEL SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ALFASIGMA S.P.A. (IT) | 2020-07-30 | — | — | US | disclosed |
| US-8999979-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2015-04-07 | — | — | US | disclosed |
| US-8853240-B2 | Compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2014-10-07 | — | — | US | disclosed |
| EP-2361251-B1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2014-04-30 | — | — | EP | disclosed |
| US-20140100220-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2014-04-10 | — | — | US | disclosed |
| US-8563545-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2013-10-22 | — | — | US | disclosed |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV | 2012-06-07 | — | — | US | disclosed |
| EP-2445911-A1 | 5-PHENYL-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | Galapagos N.V. (BE) | 2012-05-02 | — | — | EP | disclosed |
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ALFASIGMA S.P.A. (IT) | 2010-12-30 | — | — | US | disclosed |
| WO-2010149769-A1 | 5-PHENYL-[1,2,4 ]TRIAZOLO[1,5-A]PYRIDIN-2-YL CARBOXAMIDES AS JAK INHIBITORS | GALAPAGOS NV (BE) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010010190-A1 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331319-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | PARP1 4586/4885IKBKB 65/4885CHUK 45/4885 |
| US-10919890-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | PARP1 2434/4885IKBKB 331/4885CHUK 472/4885 |
| US-11667633-B2 | Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL6, JAK1, COL1A1 | PARP1 2434/4885IKBKB 331/4885CHUK 472/4885 |
| US-20140100220-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | PARP1 4586/4885IKBKB 65/4885CHUK 45/4885 |
| US-20120142678-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | PARP1 4586/4885IKBKB 65/4885CHUK 45/4885 |
| US-12042498-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | PARP1 4375/4885IKBKB 47/4885CHUK 30/4885 |
| US-20210369727-A1 | NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL6, JAK1, BMP6 | PARP1 4586/4885IKBKB 65/4885CHUK 45/4885 |
| US-11000528-B2 | Compound useful for the treatment of degenerative and inflammatory diseases | IL6, JAK1, BMP6 | PARP1 4375/4885IKBKB 47/4885CHUK 30/4885 |
| US-20230406857-A1 | SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | IL6, JAK1, COL1A1 | PARP1 2434/4885IKBKB 331/4885CHUK 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.